EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing

Daniele Lavacchi, Sara Fancelli iD, Eleonora Buttitta, Gianmarco Vannini, Alessia Guidolin, Costanza Winchler, Enrico Caliman iD, Agnese Vannini, Elisa Giommoni, Marco Brugia, Fabio Cianchi iD, Serena Pillozzi iD und 2 weitere

International Journal of Molecular Sciences · 02.03.2023 · 24 (5) · 4877

DOI: 10.3390/ijms24054877 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.03.2023. Verfasst von Daniele Lavacchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no defined molecularly based treatment strategy. Unfortunately, nearly half of patients experience disease recurrence despite standard treatments (neoadjuvant and/or adjuvant chemotherapy/chemoradiotherapy and surgery). In this review, we summarize the evidence of potential tailored approaches in perioperative treatment of G/GEJ cancer, with a special focus on patients with human epidermal growth factor receptor-2(HER2)-positive and microsatellite instability-high (MSI-H) tumors. In patients with resectable MSI-H G/GEJ adenocarcinoma, the ongoing INFINITY trial introduces the concept of non-operative management for patients with complete clinical-pathological-molecular response, and this could be a novel and potential practice changing strategy. Other pathways involving vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), claudin18 isoform 2 (CLDN18.2), and DNA damage repair proteins are also described, with limited evidence until now. Although tailored therapy appears to be a promising strategy for resectable G/GEJ cancer, there are several methodological issues to address: inadequate sample size for pivotal trials, underestimation of subgroup effects, and choice of primary endpoint (tumor-centered vs. patient-centered endpoints). A better optimization of G/GEJ cancer treatment allows maximizing patient outcomes. In the perioperative phase, although caution is mandatory, times are changing and tailored strategies could introduce new treatment concepts. Overall, MSI-H G/GEJ cancer patients possess the characteristics to be the subgroup that could receive the most benefit from a tailored approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsStomach NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantNeoplasm Recurrence, LocalTreatment Outcome

Stichwörter der Autor:innen

Claudin18.2HER2MSI-Hperioperative GC

Autor:innen und Institutionen

  • Clinical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
  • Medical Oncology Unit, Careggi University Hospital, 50134 Florence, Italy.
  • Unit of Digestive Surgery, Careggi University Hospital, 50134 Florence, Italy.
  • Department of Health Science, University of Florence, 50134 Florence, Italy.

ORCID-Profile: Sara Fancelli, Enrico Caliman, Fabio Cianchi, Serena Pillozzi

Zitieren

APA

Lavacchi, D., Fancelli, S., Buttitta, E., Vannini, G., Guidolin, A., Winchler, C., Caliman, E., Vannini, A., Giommoni, E., Brugia, M., Cianchi, F., Pillozzi, S., Roviello, G., & Antonuzzo, L. (2023). Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. International Journal of Molecular Sciences, 24(5), 4877. https://doi.org/10.3390/ijms24054877

Vancouver

Lavacchi D, Fancelli S, Buttitta E, Vannini G, Guidolin A, Winchler C, et al. Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. International Journal of Molecular Sciences. 2023;24(5):4877. doi:10.3390/ijms24054877

BibTeX
@article{Lavacchi2023,
  author = {Lavacchi, Daniele and Fancelli, Sara and Buttitta, Eleonora and Vannini, Gianmarco and Guidolin, Alessia and Winchler, Costanza and Caliman, Enrico and Vannini, Agnese and Giommoni, Elisa and Brugia, Marco and Cianchi, Fabio and Pillozzi, Serena and Roviello, Giandomenico and Antonuzzo, Lorenzo},
  title = {Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {4877},
  doi = {10.3390/ijms24054877}
}
Kostenlos starten →